Rheumatology · Oncology ·
Review outlines diagnosis and management of checkpoint inhibitor-associated arthritis
A review describes the clinical features and management of inflammatory arthritis associated with immune checkpoint inhibitors. It emphasizes that symptoms can persist after treatment ends and that care aims to control arthritis while enabling cancer therapy to continue.
- Arthritis can persist after checkpoint inhibitor discontinuation.
- Diagnosis requires excluding cancer and other causes of joint symptoms.
- Management balances symptom control with ongoing cancer treatment.
- Treatment decisions should be multidisciplinary and individualized.
Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) is described as the most common rheumatological immune-related adverse event. The review outlines varied presentations, including polyarticular and oligoarticular disease, and notes that symptoms may persist long after checkpoint inhibitor treatment stops. Unlike many idiopathic inflammatory arthritides, ICI-IA is predominantly seronegative, so assessment relies on clinical recognition and exclusion of other causes, including metastatic cancer, fracture and other immune-related adverse events.
The review describes treatment with glucocorticoids and increasing use of conventional and biologic disease-modifying antirheumatic drugs. The stated aim is to optimize joint symptoms and quality of life while facilitating continuation of cancer therapy, rather than necessarily achieving arthritis remission. Treatment decisions should be shared among the patient, oncologist, rheumatologist and other involved clinicians, considering arthritis severity, cancer indication, alternative cancer treatments and patient goals. The authors advise using immunosuppression at the lowest effective dose for the shortest possible time to optimize tumour outcomes. The source is a review; it provides no study sample or comparative treatment-effect estimates.
In practice
For patients developing joint symptoms during or after immune checkpoint inhibitor therapy, the review highlights the need to consider ICI-associated arthritis while excluding mimics such as metastatic cancer, fracture and other immune-related adverse events. Symptoms may continue after immunotherapy ends. Management is described as aiming to control arthritis and support continuation of cancer treatment, using glucocorticoids or DMARDs as appropriate and minimizing immunosuppression where possible. Decisions should be individualized and multidisciplinary; this review does not provide comparative evidence establishing a preferred regimen.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Reviews Rheumatology: Immune checkpoint inhibitor-associated inflammatory arthritis ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.